- Univercells Technologies launches scale-X™ nitro controller for large-scale viral and advanced therapy manufacturing.
- The controller promises cost-effectiveness, reduced footprint, and enhanced scalability from R&D to commercial levels within eight months.
- Pre-orders begin in June 2025, with shipments expected in early 2026.
Univercells Technologies, a part of Donaldson Life Sciences, has announced the launch of its scale-X™ nitro controller, expanding their innovative bioprocessing solutions. This new controller, designed for the 200 and 600 m² scale-X nitro bioreactors, enhances their existing scale-X platform, offering a cost-effective and user-friendly solution for viral and advanced therapy manufacturing.
The scale-X nitro controller provides high productivity and allows for rapid scalability from research and development to commercial production in just eight months. It supports both adherent and suspension cell cultures, making it suitable for a broad range of applications such as viral vaccines, exosomes, LV and AAV vector production, oncolytic viruses, and recombinant proteins.
Marie Jourdan, Director of the Bioprocessing Product Portfolio at Univercells Technologies, highlighted the controller's potential to help biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMOs), and academic institutions scale up operations without additional complexity or cost. The system is compact, with a 1.6 m² footprint and a height under 2 meters, facilitating easy integration into production suites.
The scale-X nitro controller's efficiency is underscored by its ability to reduce production costs by 36% to 82% compared to other adherent methods, enhancing economic feasibility for manufacturers. This launch reinforces Univercells Technologies' commitment to providing scalable and accessible solutions for advanced therapy and vaccine developers globally.
Pre-orders for the scale-X™ nitro controller will commence in June 2025, and shipments are anticipated to start in early 2026. For more information, interested parties can visit Univercells Technologies' website or connect with them during the ASGCT event in New Orleans from May 13-17, 2025.
Donaldson Company (DCI, Financial), known for its pioneering efforts in filtration solutions, continues to expand its footprint in the Life Sciences sector through such innovations. With a market cap of $7.83 billion, Donaldson maintains a strong presence in the specialty industrial machinery sector.
